share_log

艾美疫苗：自願性公告 - 控股股東進一步持續增持H股股份

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER

Hong Kong Stock Exchange ·  Apr 18 07:44
Summary by Moomoo AI
艾美疫苗股份有限公司（「本公司」）於2024年4月18日發布自願性公告，宣布公司控股股東、董事會主席、執行董事及首席執行官周延先生自2023年11月14日至2024年4月15日期間，透過公開市場以自有資金合計10,420,212.00港幣增持公司H股股份。本次增持反映了周延先生對公司內在價值及未來增長潛力的信心，並未觸發強制要約責任，也未導致控制權變化。公司運營、財務狀況及產品銷售均保持正常，疫苗研發進展符合計劃。公告指出，此舉有利於公司長期戰略布局的實現，並強調股東及潛在投資者應謹慎買賣公司證券。
艾美疫苗股份有限公司（「本公司」）於2024年4月18日發布自願性公告，宣布公司控股股東、董事會主席、執行董事及首席執行官周延先生自2023年11月14日至2024年4月15日期間，透過公開市場以自有資金合計10,420,212.00港幣增持公司H股股份。本次增持反映了周延先生對公司內在價值及未來增長潛力的信心，並未觸發強制要約責任，也未導致控制權變化。公司運營、財務狀況及產品銷售均保持正常，疫苗研發進展符合計劃。公告指出，此舉有利於公司長期戰略布局的實現，並強調股東及潛在投資者應謹慎買賣公司證券。
EMERY VACCINES CO., LTD. (THE “COMPANY”) ISSUED A VOLUNTARY ANNOUNCEMENT ON 18 APRIL 2024 ANNOUNCING THAT MR. CHU YAN, THE HOLDING SHAREHOLDER, CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER OF THE COMPANY FROM 14 NOVEMBER 2023 TO 15 APRIL 2024 WITH EQUITY CAPITAL THROUGH THE OPEN MARKET FOR A TOTAL OF 10,420,220,220 HK$12.00 increase in Company H shares. This increase reflects Mr. Zhou Yan's confidence in the company's intrinsic value and future growth potential. It did not trigger mandatory covenant liability and did not result in a change of control. The company's operations, financial condition and product sales have remained normal, and vaccine R&D is progressing according to plan. The announcement notes that this is conducive to the achievement of the Company's long-term strategic structure and stresses that shareholders and potential investors should buy and sell the Company's securities with caution.
EMERY VACCINES CO., LTD. (THE “COMPANY”) ISSUED A VOLUNTARY ANNOUNCEMENT ON 18 APRIL 2024 ANNOUNCING THAT MR. CHU YAN, THE HOLDING SHAREHOLDER, CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER OF THE COMPANY FROM 14 NOVEMBER 2023 TO 15 APRIL 2024 WITH EQUITY CAPITAL THROUGH THE OPEN MARKET FOR A TOTAL OF 10,420,220,220 HK$12.00 increase in Company H shares. This increase reflects Mr. Zhou Yan's confidence in the company's intrinsic value and future growth potential. It did not trigger mandatory covenant liability and did not result in a change of control. The company's operations, financial condition and product sales have remained normal, and vaccine R&D is progressing according to plan. The announcement notes that this is conducive to the achievement of the Company's long-term strategic structure and stresses that shareholders and potential investors should buy and sell the Company's securities with caution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more